Coloplast A/S reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2013. For the quarter, the company reported revenue of DKK 2,842 million compared to DKK 2,692 million a year ago. Operating profit before interest, tax, depreciation and amortisation (EBITDA) was DKK 993 million compared to DKK 898 million a year ago. Operating profit (EBIT) was DKK 859 million compared to DKK 770 million a year ago. Profit before tax was DKK 855 million compared to DKK 690 million a year ago. Profit for the period was DKK 635 million compared to DKK 514 million a year ago. Cash flow from operating activities was DKK 591 million compared to DKK 578 million a year ago. Investments in property, plant and equipment, gross were DKK 83 million compared to DKK 73 million a year ago. Return on equity was 41% compared to 44% a year ago. Free cash flow was DKK 487 million compared to DKK 506 million a year ago. Earnings per Share (EPS), diluted were DKK 2.95 compared to DKK 2.40 a year ago. For the six months period, the company reported revenue of DKK 5,707 million compared to DKK 5,346 million a year ago. Operating profit before interest, tax, depreciation and amortisation (EBITDA) was DKK 2,012 million compared to DKK 1,715 million a year ago. Operating profit (EBIT) was DKK 1,756 million compared to DKK 1,463 million a year ago. Profit before tax was DKK 1,687 million compared to DKK 1,340 million a year ago. Profit for the period was DKK 1,252 million compared to DKK 998 million a year ago. Cash flow from operating activities was DKK 1,059 million compared to DKK 801 million a year ago. Investments in property, plant and equipment, gross were DKK 170 million compared to DKK 137 million a year ago. Return on equity was 40% compared to 42% a year ago. Free cash flow was DKK 872 million compared to DKK 668 million a year ago. Earnings per Share (EPS), diluted were DKK 5.83 compared to DKK 4.68 a year ago. CapEx amounted to DKK 183 million for the first half of fiscal 2013. The company provided earnings guidance for the fiscal year 2013. For 2013, the company’s organic revenue growth of 6% to 7% and growth of 5% to 6% in DKK. Expects EBIT margin of 31% to 32%, both at constant exchange rates and in DKK. Capital expenditure is expected to be around DKK 400 million. The effective tax rate is expected to be 25% to 26%.

Coloplast A/S resolved to exercise the authorisation, provided by the shareholders at the annual general meeting held on December 11, 2012, to pay extraordinary dividends. The company will pay DKK 3 per share for a total dividend payout of DKK 634 million. The dividend will be paid on the basis of share-holdings registered in shareholders custody accounts on May 8, 2013, which means that transactions made up to May 3, 2013 inclusive will be eligible for dividends. Dividends will be at shareholders disposal on May 13, 2013.

Coloplast A/S Presents at UBS Global Healthcare Conference, May-21-2013 10:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Lars Rasmussen, Chief Executive Officer and President.